SBRT for Unresectable Pancreatic Cancer Can Improve Local Control With Minimal Toxicity

International Journal of Radiation Oncology, Biology, Physics, Volume 99, Issue 2, 2017 Oct 1 | Ng, Sweet Ping, MBBS; Herman, Joseph M., MD, MSc
This patient (1) who initially had borderline resectable pancreas cancer has had progression after FOLFIRINOX. Because of >180° involvement of the superior mesenteric artery, she has unresectable disease. Reasonable options include: ( 1 ) conti...

http://ift.tt/2wzm7mS